The Potential of Biologics for the Treatment of Asthma

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2012 Dec 1

PMID 23197041

Citations 78

Authors

Girolamo Pelaia

Alessandro Vatrella

Rosario Maselli

Affiliations

Soon will be listed here.

Abstract

Recent advances in the knowledge of asthma pathobiology suggest that biological therapies that target cytokines can be potentially useful for the treatment of this complex and heterogeneous airway disease. The use of biologics in asthma has been established with the approval of the humanized monoclonal immunoglobulin E-targeted antibody omalizumab (Xolair; Genentech/Novartis) as an add-on treatment for inadequately controlled disease. Furthermore, evidence is accumulating in support of the efficacy of other biologics, such as interleukin-5 (IL-5)- and IL-13-specific drugs. Therefore, these new developments are changing the scenario of asthma therapies, especially with regard to more severe disease. The variability among patients' individual therapeutic responses highlights that it will be necessary to characterize the different asthma subtypes so that phenotype-targeted treatments based on the use of biologics can be implemented.

Citing Articles

Gingival-derived mesenchymal stem cells alleviate allergic asthma inflammation via HGF in animal models.

Fang Q, Wu W, Xiao Z, Zeng D, Liang R, Wang J iScience. 2024; 27(5):109818.

PMID: 38766356 PMC: 11099335. DOI: 10.1016/j.isci.2024.109818.

Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.

Akenroye A, Segal J, Zhou G, Foer D, Li L, Alexander G J Allergy Clin Immunol. 2023; 151(5):1269-1276.

PMID: 36740144 PMC: 10164684. DOI: 10.1016/j.jaci.2023.01.020.

Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma.

Kandil R, Baldassi D, Bohlen S, Muller J, Jurgens D, Bargmann T J Control Release. 2023; 354:305-315.

PMID: 36634709 PMC: 7614985. DOI: 10.1016/j.jconrel.2023.01.014.

TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts.

Zhou Z, Liang S, Zhou Z, Liu J, Zhang J, Meng X Respir Res. 2023; 24(1):8.

PMID: 36627645 PMC: 9832654. DOI: 10.1186/s12931-023-02313-9.

miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma.

Rodrigo-Munoz J, Gil-Martinez M, Lorente-Sorolla C, Garcia-Latorre R, Valverde-Monge M, Quirce S Front Immunol. 2022; 13:858722.

PMID: 35432357 PMC: 9010740. DOI: 10.3389/fimmu.2022.858722.

References

Gruenberg D, Busse W . Biologic therapies for asthma. Curr Opin Pulm Med. 2009; 16(1):19-24. DOI: 10.1097/MCP.0b013e3283328398. View

Borish L, Nelson H, Lanz M, Claussen L, Whitmore J, Agosti J . Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999; 160(6):1816-23. DOI: 10.1164/ajrccm.160.6.9808146. View

Singh D, Kane B, Molfino N, Faggioni R, Roskos L, Woodcock A . A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010; 10:3. PMC: 2820465. DOI: 10.1186/1471-2466-10-3. View

Salvato G . Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax. 2001; 56(12):902-6. PMC: 1745985. DOI: 10.1136/thorax.56.12.902. View

Terracciano R, Preiano M, Palladino G, Carpagnano G, Foschino Barbaro M, Pelaia G . Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics. 2011; 11(16):3402-14. DOI: 10.1002/pmic.201000828. View

Veldhoen M, Uyttenhove C, Van Snick J, Helmby H, Westendorf A, Buer J . Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008; 9(12):1341-6. DOI: 10.1038/ni.1659. View

Matsumoto K, Inoue H, Fukuyama S, Kan-O K, Eguchi-Tsuda M, Matsumoto T . Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma. Respirology. 2009; 14(2):187-94. DOI: 10.1111/j.1440-1843.2008.01472.x. View

Henderson Jr W, Chi E, Maliszewski C . Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol. 2000; 164(2):1086-95. DOI: 10.4049/jimmunol.164.2.1086. View

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

10.

Wenzel S . Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012; 42(5):650-8. DOI: 10.1111/j.1365-2222.2011.03929.x. View

11.

Pelaia G, Renda T, Romeo P, Busceti M, Maselli R . Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis. 2009; 2(6):409-21. DOI: 10.1177/1753465808100431. View

12.

Collins P, Marleau S, Jose P, Williams T . Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med. 1995; 182(4):1169-74. PMC: 2192289. DOI: 10.1084/jem.182.4.1169. View

13.

Berry M, Hargadon B, Shelley M, Parker D, Shaw D, Green R . Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354(7):697-708. DOI: 10.1056/NEJMoa050580. View

14.

Al-Ramli W, Prefontaine D, Chouiali F, Martin J, Olivenstein R, Lemiere C . T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009; 123(5):1185-7. DOI: 10.1016/j.jaci.2009.02.024. View

15.

Provoost S, Maes T, Van Durme Y, Gevaert P, Bachert C, Schmidt-Weber C . Decreased FOXP3 protein expression in patients with asthma. Allergy. 2009; 64(10):1539-1546. DOI: 10.1111/j.1398-9995.2009.02056.x. View

16.

Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G, Chung K . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34(4):632-8. DOI: 10.1111/j.1365-2222.2004.1916.x. View

17.

Stirling R, van Rensen E, Barnes P, Chung K . Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1403-9. DOI: 10.1164/ajrccm.164.8.2010002. View

18.

Pelaia G, Gallelli L, Romeo P, Renda T, Busceti M, Proietto A . Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther. 2011; 49(12):713-21. DOI: 10.5414/cp201586. View

19.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

20.

Zhou C, Crocker I, Koenig G, Romero F, Townley R . Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma. J Asthma. 1997; 34(3):195-201. DOI: 10.3109/02770909709068189. View